Retatrutide News

Every article we’ve published on Retatrutide, newest first — 1 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.

Close-up of lined up vaccine vials casting shadows, symbolizing medical advancements and health. — Lyophilised peptide vial with an unbranded label beside a laboratory analysis printout

August 6, 2026

Retatrutide Grey Market Tested: Australian Study Checks Labels

A research letter in Drug and Alcohol Review reports laboratory analysis of vials sold under the retatrutide name in Australia — a direct look at what circulates in the retatrutide grey market. It lands while the compound itself is still years from any approval decision, with a 4,500-participant liver outcomes trial now recruiting.

RetatrutideSafety & RegulationCompounding & Supply

How this page is made. PeptideWiz News covers regulatory actions, published research, and industry developments from a fixed list of primary sources — the FDA, NIH, EMA, ClinicalTrials.gov, PubMed, peer-reviewed journals, and company press rooms. Articles are drafted with AI assistance from those sources, reviewed before publication, and always link to the original. Read the full editorial standards & corrections policy. This is journalism about peptides, not medical advice: it does not recommend any substance, does not state dosages, and is not a substitute for your provider.

← Back to all peptide news